Anika Therapeutics Files 10-K/A Amendment
Ticker: ANIK · Form: 10-K/A · Filed: Apr 26, 2024 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | 10-K/A |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $0.01, $100 million, $1 billion, $18 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K/A, Anika Therapeutics, SEC Filing, Amendment, ANIK
TL;DR
<b>Anika Therapeutics filed an amendment to its 2023 annual report, confirming its ongoing compliance with SEC filing requirements.</b>
AI Summary
Anika Therapeutics, Inc. (ANIK) filed a Amended Annual Report (10-K/A) with the SEC on April 26, 2024. Anika Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023. The company's common stock is traded on the NASDAQ Global Select Market under the ticker symbol ANIK. Anika Therapeutics is incorporated in Delaware and headquartered in Bedford, Massachusetts. The filing indicates the company has been subject to Section 13 or 15(d) filing requirements for the past 90 days. The company has submitted all required Interactive Data Files electronically for the preceding 12 months.
Why It Matters
For investors and stakeholders tracking Anika Therapeutics, Inc., this filing contains several important signals. This amendment provides updated or corrected information for the fiscal year ending December 31, 2023, which is crucial for investors to have the most accurate financial and operational data. As an accelerated filer, Anika Therapeutics is subject to more frequent and detailed reporting requirements, and this filing demonstrates adherence to those obligations.
Risk Assessment
Risk Level: low — Anika Therapeutics, Inc. shows low risk based on this filing. The filing is an amendment to a previous report, suggesting potential corrections or additions rather than new material events, thus posing a low immediate risk.
Analyst Insight
Investors should review the specific changes made in this 10-K/A filing to understand any updated disclosures or financial restatements.
Key Numbers
- 2023-12-31 — Fiscal Year End (Report Period)
- 2024-04-26 — Filing Date (Amendment Date)
- 001-14027 — SEC File Number (Company Filing Identifier)
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Registrant Name
- ANIK (company) — Trading Symbol
- NASDAQ Global Select Market (company) — Exchange
- Delaware (company) — State of Incorporation
- Bedford, Massachusetts (company) — Business Address
- 1934 Act (regulator) — SEC Act
- Rule 405 (regulator) — SEC Rule
- Regulation S-T (regulator) — SEC Regulation
FAQ
When did Anika Therapeutics, Inc. file this 10-K/A?
Anika Therapeutics, Inc. filed this Amended Annual Report (10-K/A) with the SEC on April 26, 2024.
What is a 10-K/A filing?
A 10-K/A is a amendment to a previously filed annual report, correcting or updating financial statements or disclosures. This particular 10-K/A was filed by Anika Therapeutics, Inc. (ANIK).
Where can I read the original 10-K/A filing from Anika Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Anika Therapeutics, Inc..
What are the key takeaways from Anika Therapeutics, Inc.'s 10-K/A?
Anika Therapeutics, Inc. filed this 10-K/A on April 26, 2024. Key takeaways: Anika Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2023.. The company's common stock is traded on the NASDAQ Global Select Market under the ticker symbol ANIK.. Anika Therapeutics is incorporated in Delaware and headquartered in Bedford, Massachusetts..
Is Anika Therapeutics, Inc. a risky investment based on this filing?
Based on this 10-K/A, Anika Therapeutics, Inc. presents a relatively low-risk profile. The filing is an amendment to a previous report, suggesting potential corrections or additions rather than new material events, thus posing a low immediate risk.
What should investors do after reading Anika Therapeutics, Inc.'s 10-K/A?
Investors should review the specific changes made in this 10-K/A filing to understand any updated disclosures or financial restatements. The overall sentiment from this filing is neutral.
How does Anika Therapeutics, Inc. compare to its industry peers?
Anika Therapeutics operates in the surgical and medical instruments & apparatus industry, focusing on products for orthopedic procedures.
Are there regulatory concerns for Anika Therapeutics, Inc.?
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments (10-K/A).
Industry Context
Anika Therapeutics operates in the surgical and medical instruments & apparatus industry, focusing on products for orthopedic procedures.
Regulatory Implications
The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments (10-K/A).
What Investors Should Do
- Review the specific amendments made in the 10-K/A filing for any material changes.
- Monitor future SEC filings from Anika Therapeutics for ongoing financial and operational updates.
- Verify the company's compliance status with relevant SEC regulations.
Key Dates
- 2023-12-31: Fiscal Year End — End of the reporting period for the annual report.
- 2024-04-26: Filing Date — Date the 10-K/A amendment was filed with the SEC.
Year-Over-Year Comparison
This is an amendment (10-K/A) to the previously filed annual report for the fiscal year ended December 31, 2023.
Filing Stats: 4,195 words · 17 min read · ~14 pages · Grade level 17 · Accepted 2024-04-26 08:48:24
Key Financial Figures
- $0.01 — ch Registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select
- $100 million — ing building from scratch a high-growth $100 million-plus regenerative medicine business whi
- $1 billion — ions and alliances and raised more than $1 billion in debt and equity financing Financia
- $18 b — t, of Becton, Dickinson and Company, an $18 billion, global medical technology compan
Filing Documents
- anik20231231_10ka.htm (10-K/A) — 669KB
- ex_659521.htm (EX-10.10A) — 96KB
- ex_659522.htm (EX-10.10B) — 97KB
- ex_659583.htm (EX-31.1) — 5KB
- ex_659584.htm (EX-31.2) — 5KB
- blanchard.jpg (GRAPHIC) — 3KB
- conley.jpg (GRAPHIC) — 3KB
- fischetti.jpg (GRAPHIC) — 3KB
- graph1.jpg (GRAPHIC) — 19KB
- graph2.jpg (GRAPHIC) — 67KB
- graph3.jpg (GRAPHIC) — 75KB
- henneman.jpg (GRAPHIC) — 3KB
- larsen.jpg (GRAPHIC) — 3KB
- richard.jpg (GRAPHIC) — 3KB
- thompson.jpg (GRAPHIC) — 3KB
- vogt.jpg (GRAPHIC) — 3KB
- xbullet.jpg (GRAPHIC) — 0KB
- 0001171843-24-002274.txt ( ) — 1637KB
- anik-20231231.xsd (EX-101.SCH) — 3KB
- anik-20231231_def.xml (EX-101.DEF) — 16KB
- anik-20231231_lab.xml (EX-101.LAB) — 22KB
- anik-20231231_pre.xml (EX-101.PRE) — 17KB
- anik20231231_10ka_htm.xml (XML) — 6KB
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors The following table sets forth certain information about the current directors of our Company. Directors are elected for three-year terms, to hold office until the annual meeting of stockholders or special meeting in lieu of such annual meeting at the end of their term, or until their successors are elected and qualified or until their earlier deaths, resignations, or removal. Our Board of Directors, or Board, is committed to maintaining a diverse and inclusive membership with varying experience, characteristics, and expertise that complement our business strategy. On an annual basis, the Board of Directors reviews the cumulative skill set of our Board members to insure we have the skills and experience we believe are required for Board oversight and governance of the Company and we undergo periodic Board refreshment accordingly. 6 of our 8 directors have a tenure of less than 5 years, including 2 of 8 directors being appointed in the last three years. Our directors, individually and as a group, possess a wide range of skills and experiences that are highly relevant as we transform our company, expand our business into new treatment areas and develop, manufacture, and launch new products. Our directors are strategic thinkers with high expectations for our performance. Our directors are attuned to the value and importance of diversity in all of its forms and the demands of proper Board oversight and good governance practices. The following provides information regarding our directors as of April 22, 2024: Director Name Age Director Since Term Expires Class I Directors Sheryl L. Conley 63 2021 2024 Stephen O. Richard 61 2020 2024 Jeffery S. Thompson 58 2011 2024 Class II Directors Cheryl R. Blanchard, Ph.D. 59 2018 2025 Glenn R. Larsen, Ph.D. 70 2015 2025 Class III Directors Gary P. Fischetti 63 2023 2026 John B. Henneman, III 62 2020 202